IRF8 and neoplasm: Taken collectively, these results show that HDACi can enhance basal or IFN-γ-inducible IRF-8 levels in tumor cell line models of varying malignant phenotypes and raise the possibility that HDACi may exert antitumor effects, at least in part, through IRF8-dependent mechanisms.